Administration of butorphanol with ketamine/xylazine sedation reduces the negative responses to electroejaculation in rams.

This study aimed to identify the possible advantages of administering butorphanol (BUT), associated with ketamine/xylazine (KX) sedation or not, for semen collection using electroejaculation (EE) in rams. Fifteen rams received four treatments in a cross-over design using a 2 × 2 factorial arrangement. The treatments were 1) control; 2) received KX; 3) received BUT; and 4) received both treatments. The responses to the procedures regarding heart rate, respiratory frequency, and rectal temperature were recorded, glucose and creatine kinase were measured, and semen quality was determined. More pulses were required when BUT was administered (P = 0.0067), but rams vocalized fewer times (P = 0.046). The administration of KX also tended to reduce the respiratory frequency (P = 0.068) and rectal temperature (P = 0.089), with no other effects. The administration of BUT reduced the heart rate (P < 0.0001), and there was an interactive effect between the administration of BUT and time on the heart rate (P < 0.0001), respiratory frequency (P = 0.01), and rectal temperature (P = 0.047). The administration of BUT reduced the heart rate increase immediately after EE (P < 0.0001). The respiratory frequency following EE was greater when BUT was administered (P < 0.0001), but the administration of BUT reduced the rectal temperature at the same time (P = 0.002). Glucose concentration was greater when BUT was administered (P < 0.0001). The only significant effect on the ejaculate characteristics was from the interaction between KX and BUT on sperm concentration (P = 0.004). The administration of KX alone increased sperm concentration (P = 0.035), but when BUT was added to KX, sperm concentration decreased (P = 0.002). Moreover, sperm concentration was greater when only BUT was administered than when KX and BUT were administered simultaneously (P = 0.037). The addition of BUT markedly decreased most negative responses more effectively than sedation with KX alone. In conclusion, BUT appears to be an interesting alternative to reduce the welfare concerns raised by the use of EE in rams; however, its possible effects on the ejaculate characteristics when associated with other anesthesia/sedation drugs require further study.

Response of rams to electroejaculation following the administration of oxytocin and cloprostenol with or without GnRH.

The present study aims to evaluate the effect of administering prostaglandin (250 µg cloprostenol) and oxytocin (10 UI) or a GnRH agonist (4.2 µg buserelin acetate) on rams' physiological responses to electroejaculation and the ejaculate's characteristics. The study was performed with a 2 × 2 factorial arrangement, according to whether it used oxytocin and prostaglandin (OXPGF) or GnRH. Therefore, there were four treatments: GControl = saline; GOXPGF = administration of PGF2α and oxytocin; GGnRH = administration of GnRH; administration of GOXPGF + GnRH = GnRH and PGF2α + oxytocin. An interaction between the hormonal treatments in the heart rate occurred: while the heart rate decreased when using OXPGF alone (control: 113.7 bpm vs. GOXPGF: 103.5 bpm, pooled SEM; P = 0.02), it did not modify when applying both treatments simultaneously and administering GnRH (GGnRH: 109.1 bpm vs. GOXPGF + GnRH: 111.5 bpm respectively, pooled SEM = 4.5). The respiratory rate also decreased with the administration of OXPGF (38.7 vs. 46.3 with and without OXPGF, pooled SEM = 10.0, P = 0.003). Administering OXPGF also tended to decrease the temperature (38.77 °C vs. 38.94 °C, with and without OXPGF, respectively, pooled SEM = 0.06; P = 0.056). Blood glucose increased with the administration of OXPGF from 58.7 mg/dL to 62.4 mg/dL (pooled SEM = 1.3, P = 0.014) and varied with time. CK concentrations increased from 641.8 mg/dL to 881.7 mg/dL (pooled SEM = 50.6) with the administration of OXPGF. GnRH administration decreased cortisol concentration from 7.3 ng/mL to 2.1 ng/mL (pooled SEM = 1.4; P = 0.04). The treatments had no effects on the time required for EE, the pulse at which the animals began and ended the ejaculation, or the vocalizations emitted during EE. There were no effects in any evaluated sperm variable. The research concluded that the administration of oxytocin and analogs of PGF2alpha decreased the stress response to electroejaculation, as well as administering GnRH agonist was slightly effective as it only decreased cortisol concentration. Also, these treatments, either alone or combined, did not affect the characteristics of the ejaculate collected.

Efficiency of different hormonal treatments for estrus synchronization in tropical Santa Inês sheep.

The aim of this study was to evaluate the effect of (i) the duration of hormone treatment with progestogen sponges during the seasonal anestrus and (ii) the administration of two doses of prostaglandin at 7 days apart during the breeding season on reproductive parameters of Santa Inês ewes. In experiment 1, 32 ewes received intravaginal MAP sponges for 6 (G6 days), 9 (G9 days), or 12 (G12days) days and 75 µg D-cloprostenol i.m. and 300 IU eCG i.m. 1 day before sponge removal. In experiment 2, 23 ewes received two doses of 0.48-mg sodium cloprostenol i.m. 7 days apart. Ovarian follicular dynamic was assessed through transrectal ultrasonography. Blood samples were collected daily to determine progesterone concentrations. In experiment 1, estrus and ovulation rates did not differ (P > 0.05) among protocols and between cyclic and acyclic ewes at the beginning of the experiment. The G9 days treatment showed a lower dispersion of ovulations in relation to onset of estrus when compared to G6 days and G12 days. In experiment 2, all ewes exhibit estrus and ovulated after the second dose of prostaglandin, although ewes that were in diestrus at D0 showed subluteal concentrations of progesterone during the follicle development stage of the treatment. In conclusion, the use of progestogen device during 9 days promotes lower dispersion of ovulation when compared to its use for 6 or 12 days, and the protocol of two doses of prostaglandin 7 days apart synchronizes estrus efficiently but results in follicular development under low progesterone concentrations.